TRVI
Trevi TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
If Trevi secures positive clinical signals and extends runway without heavy dilution, shares could re-rate toward small-cap biotech multiples driven by program value and potential partnerships.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.1.
What can break
Failed trials, negative safety signals, or dilutive financings could drive the equity toward zero; cash runway and binary readouts are main downside drivers.
Momentum
89
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.61 · Bull $1.22 · Bear $0.30
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $27.33
Why
Momentum89 · Δ7d -1.1
Value41 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
89
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
-0.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 88.6 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$2.38B
Beta
0.96
Shares Out
141.98M
P/E (TTM) · Derived
-52.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-47.52
Rev YoY
-
EPS YoY
+3.1%
Gross Margin
-
Op Margin
-
Net Debt
-$187.51M
Current Ratio
24.75
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology